S
Samuel H. Sigal
Researcher at Albert Einstein College of Medicine
Publications - 76
Citations - 5337
Samuel H. Sigal is an academic researcher from Albert Einstein College of Medicine. The author has contributed to research in topics: Cirrhosis & Hepatic encephalopathy. The author has an hindex of 26, co-authored 71 publications receiving 4811 citations. Previous affiliations of Samuel H. Sigal include Hospital of the University of Pennsylvania & Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Rifaximin treatment in hepatic encephalopathy.
Nathan M. Bass,Kevin D. Mullen,Arun J. Sanyal,Fred Poordad,Guy W. Neff,Carroll B. Leevy,Samuel H. Sigal,Muhammad Y. Sheikh,Kimberly Beavers,Todd Frederick,Lewis W. Teperman,Donald J. Hillebrand,Shirley Huang,Kunal Merchant,Audrey L. Shaw,Enoch Bortey,William P. Forbes +16 more
TL;DR: Over a 6-month period, treatment with rifaximin maintained remission from hepatic encephalopathy more effectively than did placebo, and also significantly reduced the risk of hospitalization involving hepaticEncephalopathy.
Journal ArticleDOI
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Jordan J. Feld,Kris V. Kowdley,Eoin Coakley,Samuel H. Sigal,David R. Nelson,Darrell H. G. Crawford,Ola Weiland,Humberto Aguilar,Junyuan Xiong,Tami Pilot-Matias,Barbara DaSilva-Tillmann,Lois Larsen,Thomas Podsadecki,B. Bernstein +13 more
TL;DR: In previously untreated patients with HCV genotype 1 infection and no cirrhosis, a 12-week multitargeted regimen of ABT-450/r-ombitasvir and dasabuvir with ribavirin was highly effective and was associated with a low rate of treatment discontinuation.
Journal ArticleDOI
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.
Arun J. Sanyal,Thomas D. Boyer,Guadalupe Garcia-Tsao,Frederick Regenstein,Lorenzo Rossaro,Beate Appenrodt,Andres T. Blei,Veit Gülberg,Samuel H. Sigal,Peter Teuber +9 more
TL;DR: Terrlipressin is an effective treatment to improve renal function in HRS type 1 and transplantation-free survival was similar between study groups; HRS reversal significantly improved survival at day 180.
Journal ArticleDOI
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
John G. McHutchison,Geoffrey Dusheiko,Mitchell L. Shiffman,Maribel Rodriguez-Torres,Samuel H. Sigal,M. Bourliere,Thomas Berg,Stuart C. Gordon,Fiona Campbell,Dickens Theodore,Nicole Jill-Marie Blackman,Julian Jenkins,Nezam H. Afdhal +12 more
TL;DR: Eltrombopag therapy increases platelet counts in patients with thrombocytopenia due to HCV-related cirrhosis, thereby permitting the initiation of antiviral therapy.
Journal ArticleDOI
The liver as a stem cell and lineage system.
TL;DR: The lineage model provides clarity and insights into many aspects of liver biology and disease including the limited proliferative ability of in vitro parenchymal cultures, liver regeneration, gene expression, viral infection, hepatocellular carcinogenesis, liver cell transplantation, and aging.